For example, in the Medicare population, insurance coverage policy restricts genetic testing to just one occurrence; therefore, if patients who had Medicare coverage for BRCA1 and BRCA2 analysis and received a negative result for a mutation in either gene, they would have out-of-pocket expenses for any further testing unless they met criteria for a separate hereditary cancer syndrome. The gene discussed is BRCA2; the disease is Inherited cancer-predisposing syndrome.